Canagliflozin Tied to Reduction in HbA1c in Children, Teens With T2DM

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 6, 2025.

via HealthDay

WEDNESDAY, Aug. 6, 2025 -- Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus (T2DM), according to a study published online Aug. 5 in the Annals of Internal Medicine.

Ulhas Nadgir, M.D., from Sutter Medical Group in Sacramento, California, and colleagues assessed the safety and efficacy of canagliflozin in children and adolescents aged 10 years or older with T2DM in a phase 3 randomized, placebo-controlled multicenter study conducted in 104 sites in 10 countries. Participants were randomly assigned to canagliflozin (100 mg) or placebo once daily (84 and 87 individuals, respectively); at week 13, participants with week 12 readings of 7 percent or higher for HbA1c and at least 60 mL/min/1.73 m2 for estimated glomerular filtration rate were randomly assigned to continue receiving 100 mg canagliflozin (or placebo) or to have their dose uptitrated to 300 mg (or placebo).

The researchers found that the HbA1c reduction from baseline was significantly greater with canagliflozin versus placebo at week 26 (difference in least-squares means, −0.76 percent). A higher proportion of participants achieved HbA1c levels below 6.5 percent with canagliflozin versus placebo (36.3 versus 14.0 percent, respectively). Among those who received canagliflozin and placebo, treatment-emergent adverse events occurred in 77.4 and 74.7 percent, respectively, and serious treatment-emergent adverse events occurred in 9.5 and 5.7 percent, respectively.

"The data from this trial provide support for the use of canagliflozin in the clinical management of T2DM in children and adolescents aged 10 years or older," the authors write.

The study was funded by Johnson & Johnson, the manufacturer of canagliflozin.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-07 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords